Education
About Us
Working with TipRanks
Follow Us
Annovis Bio (ANVS)
NYSE:ANVS
ANVS Stock Chart & Stats
$4.92
-$0.04(-0.79%)
At close: 4:00 PM EST
$4.92
-$0.04(-0.79%)
Day’s Range― - ―
52-Week Range$1.11 - $7.39
Previous CloseN/A
Volume368.97K
Average Volume (3M)2.69M
Market Cap
$130.39M
Enterprise Value$25.46M
Total Cash (Recent Filing)$15.29M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta3.19
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding26,502,890
10 Day Avg. Volume6,932,240
30 Day Avg. Volume2,694,492
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)6.58
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.67Price Target Upside137.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.34
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biomarker DataAnnovis announced novel biomarker data supporting the disease-modifying potential of Buntanetap in Alzheimer's disease.
Clinical Trial ProgressThe Phase 3 study in early Alzheimer's disease is progressing with all clinical sites activated and the first patients completing the 6-month treatment period.
Regulatory ProgressAnnovis announced a Type C meeting with the FDA is scheduled to discuss the development pathway for buntanetap in Parkinson's disease dementia.
Bears Say
Financing NeedsThe need for financing remains a key consideration.
Price Target ReductionReducing the 12-month price target to $10 from $12 reflects a lengthier time to potential approval of buntanetap.
Risk FactorsRisks include failure to initiate trials in a timely manner, negative clinical data for buntanetap, inability to establish partnerships to commercialize buntanetap, failure to secure approval, slower-than-anticipated market uptake, and possible medium-term dilution risk.
Annovis Bio News
ANVS FAQ
What was Annovis Bio’s price range in the past 12 months?
Annovis Bio lowest stock price was $1.11 and its highest was $7.39 in the past 12 months.
What is Annovis Bio’s market cap?
Annovis Bio’s market cap is $130.39M.
When is Annovis Bio’s upcoming earnings report date?
Annovis Bio’s upcoming earnings report date is May 19, 2026 which is in 172 days.
How were Annovis Bio’s earnings last quarter?
Annovis Bio released its earnings results on Nov 12, 2025. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.377 by $0.007.
Is Annovis Bio overvalued?
According to Wall Street analysts Annovis Bio’s price is currently Undervalued.
Does Annovis Bio pay dividends?
Annovis Bio does not currently pay dividends.
What is Annovis Bio’s EPS estimate?
Annovis Bio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Annovis Bio have?
Annovis Bio has 26,502,890 shares outstanding.
What happened to Annovis Bio’s price movement after its last earnings report?
Annovis Bio reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.377. Following the earnings report the stock price went up 15.166%.
Which hedge fund is a major shareholder of Annovis Bio?
Currently, no hedge funds are holding shares in ANVS
Annovis Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.67 (137.20% Upside)
$11.67 (137.20% Upside)
Blogger Sentiment
Bullish
ANVS Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $2.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.6%
Last 30 Days ▲ 18.7%
Last 30 Days ▲ 18.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-25.00%
12-Months-Change
Fundamentals
Return on Equity
-246.14%
Trailing 12-Months
Asset Growth
19.69%
Trailing 12-Months
Company Description
Annovis Bio
Annovis Bio (ANVS) is a clinical-stage pharmaceutical company focused on developing innovative therapies for neurodegenerative diseases. The company is primarily engaged in the research and development of drugs aimed at treating conditions such as Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative disorders. Annovis Bio is committed to creating solutions that can halt or reverse the progression of these debilitating diseases by targeting the underlying biological pathways involved in neurodegeneration.
ANVS Stock 12 Month Forecast
Average Price Target
$11.67
▲(137.20% Upside)
Technical Analysis
Generation Bio
―
PolyPid
―
BioAtla
―
Coeptis Therapeutics Holdings
―
MiNK Therapeutics
―
Ownership Overview
14.99% Insiders
3.33% Mutual Funds
0.73% Other Institutional Investors
78.44% Public Companies and
Individual Investors